Kisqali 200mg is indicated in combination with letrozole which an aromatase inhibitor for the treatment for women with breast cancer.



21 tablets


Kisqali 200mg belongs to selective cyclin-dependent kinase inhibitor, a class of drugs which help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can allow cancer cells to develop and divide too fastly. Aiming CDK4/6 with improve precision may play a role in providing that cancer cells do not continue to multiply uncontrollably.

Mechanism of action

Ribociclib is a type of drug which can be needed along with an aromatase inhibitor to cure women with advanced hormone receptor-positive breast cancer. Ribociclib belongs to small molecule cyclin-dependent kinase (CDK) inhibitor. The drug stops proteins in the cell called cyclin-dependent kinase (CDK) 4 and CDK 6. In hormone positive breast cancer cells, inhibiting these proteins helps to block the cells from segregate to make new cells. It helps inhibit the cells from moving from G1 to S cell cycle phase in the division process. This reduce cancer growth. The Co administration of Ribociclib and an aromatase inhibitor (e.g. letrozole) is more active compared with each agent alone.


Time to maximum plasma concentration is 1-4 hr and steady state achieved is 8 days

Human plasma protein bound is 70%

Mainly metabolised by hepatic through CYP3A4 in humans.

Kisqali is eliminated through feces 69% and urine 23% Half -life is 32.6 hours



Ingredients Ribociclib
Strength 200mg
Pack 21 tablets

The prescribed dose of Kisqali is 600mg (three 200mg film coated tablets) administrated orally once daily for 21 consecutive days followed by 7 days off therapy resulting in a complete cycle of 28 days The drug Kisqali can be administrated with or without food. Overdose: overdose with Kisqali in human has experienced very limited. In case occurs provide general symptomatic and supportive measures.

Side effects

• Decreased in blood counts
• Nausea and vomiting
• Increased liver enzymes
• Fatigue
• Diarrhea
• Hair loss
• Decreased kidney function
• Lack of appetite
• Rash
• Fever
• Itching
• Insomnia
• Urinary tract infection.


Kisqali has been exposed to prolong the QT interval in a concentration-dependent manner. Based on the observed QT prolongation during therapy, Kisqali may needed dose interruption, reduction, or discontinuation. Avoid the combination use with tamoxifen due to increased QT prolongation. In patients with advanced or metastatic breast cancer will increases in transaminases were resulted; perform liver function test before starting treatment with Kisqali; based on severity of the transaminase elevations, Kisqali may require dose interference, reduction or stopping.


  • Kisqali 200mg co administration with strong CYP3A4 inhibitor will increased Ribociclib exposure in healthy subjects but this combination cannot be avoided, so reduce the dose of Kisqali to 400mg once daily
  • Kisqali 200mg co administration with strong CYP3A4 inducers will decreased Ribociclib exposure in healthy subjects by 89%
  • Concomitant use of midazolam with multiple doses of Kisqali will increased the midazolam exposure by 3.8-fold in healthy subjects.



There are no studies with the use of Kisqali 200mg in pregnant women to inform drug-associated risks. Hence avoid becoming pregnancy during Kisqali 200mg treatment

Erleada is not indicated for female patients

The drug Kisqali is store at 20°C to 25°C.

If dose is missed the have the dose immediately before next dose timing reaches or skip the missed dose and continue the regular schedule. Consult doctors regarding missed dose.


Quick Contact

Prescription upload


Blueberrypharma.com , a fully licensed and regulated pharmacy medicine, takes all precautions to strictly abide by the laws and regulations set forth in the dispensing of prescription medications. By placing the order for your prescription medicines, you acknowledge and accept the following terms regarding the purchase of any prescription medicines.

Blueberrypharma.com will not dispense any prescription medication without a valid prescription from a licensed physician.

If you are ordering prescription medication(s), you hereby confirm that you will send us a scanned copy of your valid prescription(s) via email, fax, Whatsapp, or by post, and this prescription shall then be subject to the scrutiny of and approval by our qualified Pharmacists.

The drug information provided in the Blueberrypharma.com is for informative purposes only and this Website is not intended to provide diagnosis, treatment or medical advice. We are not liable for any adverse effects or harm to you as a result of your reliance on the information in the Website.

Blueberrypharma.com requires either the User or Customer or the Caregiver to confirm he/she is completely aware of the indications, side effects, drug interactions, effects of missed dose or overdose of the medicines he/she orders from us. It is imperative to seek professional advice from your physician before purchasing or consuming any medicine from Blueberrypharma.com

At Blueberrypharma.com , a Caregiver can order prescription medicines on your behalf.